A

Canadian online pharmacy company that figured prominently in a scandal several years ago over a counterfeit cancer medicine sold to U.S. doctors has been fined $34 million, a penalty that a nonprofit advocacy group with ties to the pharmaceutical industry called a “slap on the wrist.”

Companies controlled by Canada Drugs had sold $78 million in mislabeled and unapproved medicines, including two counterfeit batches of the Avastin cancer treatment, that were made in several countries, according to federal prosecutors. The version of Avastin that was sold to U.S. doctors in 2011 did not contain any active ingredient. The brand-name medicine is marketed by Roche.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.